PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 56 filers reported holding PRELUDE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 2.40 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $285,457 | -10.7% | 74,923 | +11.1% | 0.00% | – |
| Q1 2024 | $319,604 | +7.8% | 67,427 | -2.9% | 0.00% | – |
| Q4 2023 | $296,616 | +41.8% | 69,465 | +2.6% | 0.00% | – |
| Q3 2023 | $209,156 | +95.4% | 67,688 | +184.5% | 0.00% | – |
| Q2 2023 | $107,046 | -62.1% | 23,788 | -51.9% | 0.00% | – |
| Q1 2023 | $282,127 | +196.3% | 49,496 | +214.0% | 0.00% | – |
| Q4 2022 | $95,215 | +66021.5% | 15,764 | -27.5% | 0.00% | – |
| Q3 2022 | $144 | -37.9% | 21,735 | -50.9% | 0.00% | – |
| Q2 2022 | $232 | -99.9% | 44,295 | +83.9% | 0.00% | – |
| Q1 2022 | $166,000 | -88.2% | 24,090 | -78.7% | 0.00% | – |
| Q4 2021 | $1,411,000 | +420.7% | 113,335 | +1208.9% | 0.00% | – |
| Q3 2021 | $271,000 | -49.2% | 8,659 | -53.5% | 0.00% | – |
| Q2 2021 | $533,000 | -71.7% | 18,617 | -57.2% | 0.00% | – |
| Q1 2021 | $1,885,000 | -24.8% | 43,509 | -47.7% | 0.00% | -100.0% |
| Q3 2020 | $2,507,000 | – | 83,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,909,256 | $41,564,265 | 0.82% |
| Boxer Capital, LLC | 2,568,287 | $9,785,173 | 0.52% |
| Baker Brothers Advisors | 10,123,824 | $38,571,769 | 0.49% |
| Sio Capital Management, LLC | 320,394 | $1,220,701 | 0.33% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,133,000 | $15,746,730 | 0.26% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 123,600 | $470,916 | 0.01% |
| EXCHANGE TRADED CONCEPTS, LLC | 48,727 | $185,650 | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 18,839 | $71,777 | 0.00% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 11,074 | $42,192 | 0.00% |
| KENNEDY CAPITAL MANAGEMENT LLC | 35,283 | $134,428 | 0.00% |